Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study

Abstract Background Integrase strand transfer inhibitor–based regimens are recommended for first-line therapy in human immunodeficiency virus type 2 (HIV-2). Nonetheless, dolutegravir (DTG) clinical trial data are lacking. Methods We conducted a phase 2, single-arm, open-label trial to evaluate the...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2023-09, Vol.77 (5), p.740-748
Main Authors: Pacheco, Patrícia, Marques, Nuno, Rodrigues, Paulo, Mansinho, Kamal, Maltez, Fernando, Janeiro, Nuno, Franco, Cláudia, Trigo, Diva, Batista, Joana, Duque, Luís, Lopes, Maria João, Aleixo, Maria João, Silva, Ana Rita, Tavares, Raquel, Alves, João, Peres, Susana, Póvoas, Diana, Lino, Sara, Gomes, Perpétua, Araújo, Vânia, Lopes, Cristina
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Integrase strand transfer inhibitor–based regimens are recommended for first-line therapy in human immunodeficiency virus type 2 (HIV-2). Nonetheless, dolutegravir (DTG) clinical trial data are lacking. Methods We conducted a phase 2, single-arm, open-label trial to evaluate the safety and efficacy of a triple therapy regimen that included DTG in persons with HIV-2 (PWHIV-2) in Portugal. Treatment-naive adults receive DTG in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). Treatment efficacy was evaluated by the proportion of patients who achieved a plasma viral load (pVL)
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciad339